{1-[3-(4-fluoro-phenyl)-adamantan-1-yl]-ethyl}-(1-methyl-piperidin-4-yl)-amine | 917236-67-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {1-[3-(4-fluoro-phenyl)-adamantan-1-yl]-ethyl}-(1-methyl-piperidin-4-yl)-amine
• 英文别名: N-[1-[3-(4-fluorophenyl)-1-adamantyl]ethyl]-1-methylpiperidin-4-amine
• CAS: 917236-67-0
• 化学式: C₂₄H₃₅FN₂
• 分子量: 370.554
• InChiKey: BSPYDQMJZOHLOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  、 、 {1-[3-(4-chloro-phenyl)-adamantan-1-yl]-ethyl}-(1-methyl-piperidin-4-yl)-amine 、 、 、 {1-[3-(4-chloro-phenyl)-adamantan-1-yl]-ethyl}-(4-methyl-piperazin-1-yl)-amine 、 、 [1-(3-phenyl-adamantan-1-yl)-ethyl]-pyridin-4-ylmethyl-amine 、 、 {1-[3-(4-chloro-phenyl)-adamantan-1-yl]-ethyl}-(6-chloro-pyridin-3-ylmethyl)-amine 、 、 {1-[3-(4-chloro-phenyl)-adamantan-1-yl]-ethyl}-(2-pyridin-4-yl-ethyl)-amine 、 、 {1-[3-(4-chloro-phenyl)-adamantan-1-yl]-ethyl}-(3H-imidazol-4-ylmethyl)-amine 、 、 {1-[3-(4-chloro-phenyl)-adamantan-1-yl]-ethyl}-(2-methyl-1H-indol-5-yl)-amine. 、 、 {1-[3-(4-chloro-phenyl)-adamantan-1-yl]-ethyl}-(9-ethyl-9H-carbazol-3-yl)-amine 、 、 {1-[3-(4-chloro-phenyl)-adamantan-1-yl]-ethyl}-(9-ethyl-9H-carbazol-3-ylmethyl)-amine 、 、 9-ethyl-9H-carbazole-3-carboxylic acid {1-[3-(4-chloro-phenyl)-adamantan-1-yl]-ethyl}-amide. 、 、 1-{1-[3-(4-chloro-phenyl)-adamantan-1-yl]-ethyl}-3-(4-chloro-3-trifluoromethyl-phenyl)-urea 、 、 、 (4-bromo-thiophen-2-ylmethyl)-{1-[3-(4-chloro-phenyl)-adamantan-1-yl]-ethyl}-amine 、 、 {1-[3-(4-chloro-phenyl)-adamantan-1-yl]-ethyl}-(4-phenyl-thiophen-2-ylmethyl)-amine 以Yield=28的产率得到{1-[3-(4-fluoro-phenyl)-adamantan-1-yl]-ethyl}-(1-methyl-piperidin-4-yl)-amine
  参考文献：
  名称：

  SPHINGOSINE KINASE INHIBITORS

  摘要：

  该发明涉及取代的金刚烷化合物、其药物组合物、其制备方法以及抑制鞘氨醇激酶的方法，用于治疗或预防过度增殖性疾病、炎症性疾病或血管生成性疾病。

  公开号：

  US20060287317A1

文献信息

• Sphingosine Kinase Inhibitors
  申请人：Smith Charles D.

  公开号：US20080167352A1

  公开（公告）日：2008-07-10

  The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

  本发明涉及置换的金刚烷化合物，其药物组成物、制备过程以及抑制鞘氨醇激酶、治疗或预防过度增殖性疾病、炎症性疾病或血管生成性疾病的方法。
• Sphingosine kinase inhibitors
  申请人：Apogee Biothechnology Corporation

  公开号：EP2314574A1

  公开（公告）日：2011-04-27

  The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

  本发明涉及取代的金刚烷化合物、其药物组合物、其制备工艺以及抑制鞘氨醇激酶和治疗或预防过度增殖性疾病、炎症性疾病或血管生成性疾病的方法。
• Combination therapies for treating cancer
  申请人：RedHill Biopharma Ltd.

  公开号：US10463654B2

  公开（公告）日：2019-11-05

  Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof.

  本发明提供了通过施用至少一种选自氯法齐明、利福布汀和克拉霉素组成的组的抗生素与芳基金刚烷化合物联合治疗患者癌症的方法。在一个实施方案中，芳基金刚烷化合物是[3-(4-氯苯基)-金刚烷-1-羧酸(吡啶-4-基甲基)酰胺]或其药学上可接受的盐。
• Therapy for inhibition of single-stranded RNA virus replication
  申请人：RedHill Biopharma Ltd.

  公开号：US10543222B2

  公开（公告）日：2020-01-28

  Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, reventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.

  本研究公开了能够抑制丝状病毒在人体内复制的药物组合物。所公开的组合物可用于治疗、预防或减少丝状病毒感染的传播。一种方法包括向感染丝状病毒或暴露于丝状病毒的个体施用至少一种本公开的制剂，其中施用步骤在适当的时间段内进行，以使个体得到治疗；以及确定个体是否得到治疗，其中确定步骤包括测量病毒复制的抑制、测量病毒载量的减少或减少至少一种与丝状病毒相关的症状。
• Methods for enhancing the potency of the immune checkpoint inhibitors
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

  公开号：US10822415B2

  公开（公告）日：2020-11-03

  The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.

  本发明涉及增强免疫检查点抑制剂效力的方法。特别是，本发明涉及一种增强作为治疗方案一部分施用给受试者的免疫检查点抑制剂效力的方法，该方法包括将药学有效量的SK1抑制剂与免疫检查点抑制剂联合施用给受试者。